A data-driven approach to quality risk management

Aim: An effective clinical trial strategy to ensure patient safety as well as trial quality and efficiency involves an integrated approach, including prospective identification of risk factors, mitigation of the risks through proper study design and execution, and assessment of quality metrics in re...

Full description

Bibliographic Details
Main Authors: Demissie Alemayehu, Jose Alvir, Marcia Levenstein, David Nickerson
Format: Article
Language:English
Published: Wolters Kluwer Medknow Publications 2013-01-01
Series:Perspectives in Clinical Research
Subjects:
Online Access:http://www.picronline.org/article.asp?issn=2229-3485;year=2013;volume=4;issue=4;spage=221;epage=226;aulast=Alemayehu
id doaj-ba6cbde823b04a359bef4fe6683df17a
record_format Article
spelling doaj-ba6cbde823b04a359bef4fe6683df17a2020-11-25T00:07:09ZengWolters Kluwer Medknow PublicationsPerspectives in Clinical Research2229-34852013-01-014422122610.4103/2229-3485.120171A data-driven approach to quality risk managementDemissie AlemayehuJose AlvirMarcia LevensteinDavid NickersonAim: An effective clinical trial strategy to ensure patient safety as well as trial quality and efficiency involves an integrated approach, including prospective identification of risk factors, mitigation of the risks through proper study design and execution, and assessment of quality metrics in real-time. Such an integrated quality management plan may also be enhanced by using data-driven techniques to identify risk factors that are most relevant in predicting quality issues associated with a trial. In this paper, we illustrate such an approach using data collected from actual clinical trials. Materials and Methods: Several statistical methods were employed, including the Wilcoxon rank-sum test and logistic regression, to identify the presence of association between risk factors and the occurrence of quality issues, applied to data on quality of clinical trials sponsored by Pfizer. Results: Only a subset of the risk factors had a significant association with quality issues, and included: Whether study used Placebo, whether an agent was a biologic, unusual packaging label, complex dosing, and over 25 planned procedures. Conclusion: Proper implementation of the strategy can help to optimize resource utilization without compromising trial integrity and patient safety.http://www.picronline.org/article.asp?issn=2229-3485;year=2013;volume=4;issue=4;spage=221;epage=226;aulast=AlemayehuClinical trialcompliancequality risk managementrisk assessment and mitigation
collection DOAJ
language English
format Article
sources DOAJ
author Demissie Alemayehu
Jose Alvir
Marcia Levenstein
David Nickerson
spellingShingle Demissie Alemayehu
Jose Alvir
Marcia Levenstein
David Nickerson
A data-driven approach to quality risk management
Perspectives in Clinical Research
Clinical trial
compliance
quality risk management
risk assessment and mitigation
author_facet Demissie Alemayehu
Jose Alvir
Marcia Levenstein
David Nickerson
author_sort Demissie Alemayehu
title A data-driven approach to quality risk management
title_short A data-driven approach to quality risk management
title_full A data-driven approach to quality risk management
title_fullStr A data-driven approach to quality risk management
title_full_unstemmed A data-driven approach to quality risk management
title_sort data-driven approach to quality risk management
publisher Wolters Kluwer Medknow Publications
series Perspectives in Clinical Research
issn 2229-3485
publishDate 2013-01-01
description Aim: An effective clinical trial strategy to ensure patient safety as well as trial quality and efficiency involves an integrated approach, including prospective identification of risk factors, mitigation of the risks through proper study design and execution, and assessment of quality metrics in real-time. Such an integrated quality management plan may also be enhanced by using data-driven techniques to identify risk factors that are most relevant in predicting quality issues associated with a trial. In this paper, we illustrate such an approach using data collected from actual clinical trials. Materials and Methods: Several statistical methods were employed, including the Wilcoxon rank-sum test and logistic regression, to identify the presence of association between risk factors and the occurrence of quality issues, applied to data on quality of clinical trials sponsored by Pfizer. Results: Only a subset of the risk factors had a significant association with quality issues, and included: Whether study used Placebo, whether an agent was a biologic, unusual packaging label, complex dosing, and over 25 planned procedures. Conclusion: Proper implementation of the strategy can help to optimize resource utilization without compromising trial integrity and patient safety.
topic Clinical trial
compliance
quality risk management
risk assessment and mitigation
url http://www.picronline.org/article.asp?issn=2229-3485;year=2013;volume=4;issue=4;spage=221;epage=226;aulast=Alemayehu
work_keys_str_mv AT demissiealemayehu adatadrivenapproachtoqualityriskmanagement
AT josealvir adatadrivenapproachtoqualityriskmanagement
AT marcialevenstein adatadrivenapproachtoqualityriskmanagement
AT davidnickerson adatadrivenapproachtoqualityriskmanagement
AT demissiealemayehu datadrivenapproachtoqualityriskmanagement
AT josealvir datadrivenapproachtoqualityriskmanagement
AT marcialevenstein datadrivenapproachtoqualityriskmanagement
AT davidnickerson datadrivenapproachtoqualityriskmanagement
_version_ 1725419812226596864